{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:21:22Z","timestamp":1783088482191,"version":"3.54.6"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.7759\/cureus.111991","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:31:57Z","timestamp":1783085517000},"source":"Crossref","is-referenced-by-count":0,"title":["Association Between Diabetes Mellitus and Cytochrome P450 Family 2 Subfamily C Member 19 (CYP2C19) Loss-of-Function Allele Carriage Among Patients Undergoing Coronary Artery Bypass Grafting: A Cross-Sectional Study"],"prefix":"10.7759","author":[{"given":"Most. Sumaia","family":"Bin-Te Shawkat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.M. Hossain","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istiaq","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Mohashin","family":"Reza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Rezwanul","family":"Hoque Bulbul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira NL","year":"2020","unstructured":"Pereira NL, Farkouh ME, So D, et al.. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA. 2020, 324:761-71. 10.1001\/jama.2020.12443","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI","volume":"381","author":"Claassens DM","year":"2019","unstructured":"Claassens DM, Vos GJ, Bergmeijer TO, et al.. A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI. N Engl J Med. 2019, 381:1621-31. 10.1056\/NEJMoa1907096","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel PA","year":"2003","unstructured":"Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003, 107:2908-13. 10.1161\/01.CIR.0000072771.11429.83","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/17085381211059394","article-title":"Clopidogrel resistance is common in patients undergoing vascular and coronary interventions","volume":"31","author":"Berenson AM","year":"2023","unstructured":"Berenson AM, Hawken TN, Fort DG, Money SR, Ramee SR, Sternbergh WC 3rd, Bazan HA. Clopidogrel resistance is common in patients undergoing vascular and coronary interventions. Vascular. 2023, 31:58-63. 10.1177\/17085381211059394","journal-title":"Vascular"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.04.010","article-title":"Pharmacogenomics of clopidogrel: evidence and perspectives","volume":"128","author":"Yin T","year":"2011","unstructured":"Yin T, Miyata T. Pharmacogenomics of clopidogrel: evidence and perspectives. Thromb Res. 2011, 128:307-16. 10.1016\/j.thromres.2011.04.010","journal-title":"Thromb Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega JL","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, et al.. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009, 360:354-62. 10.1056\/NEJMoa0809171","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner AR","year":"2009","unstructured":"Shuldiner AR, O'Connell JR, Bliden KP, et al.. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009, 302:849-57. 10.1001\/jama.2009.1232","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon T","year":"2009","unstructured":"Simon T, Verstuyft C, Mary-Krause M, et al.. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009, 360:363-75. 10.1056\/NEJMoa0808227","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee CR","year":"2022","unstructured":"Lee CR, Luzum JA, Sangkuhl K, et al.. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022, 112:959-67. 10.1002\/cpt.2526","journal-title":"Clin Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.913376","article-title":"Diabetes and antiplatelet therapy in acute coronary syndrome","volume":"123","author":"Ferreiro JL","year":"2011","unstructured":"Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011, 123:798-813. 10.1161\/CIRCULATIONAHA.109.913376","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.8.2430","article-title":"Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment","volume":"54","author":"Angiolillo DJ","year":"2005","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al.. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005, 54:2430-5. 10.2337\/diabetes.54.8.2430","journal-title":"Diabetes"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1880","article-title":"CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis","volume":"306","author":"Holmes MV","year":"2011","unstructured":"Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011, 306:2704-14. 10.1001\/jama.2011.1880","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7176.116232","article-title":"How to calculate sample size for different study designs in medical research?","volume":"35","author":"Charan J","year":"2013","unstructured":"Charan J, Biswas T. How to calculate sample size for different study designs in medical research?. Indian J Psychol Med. 2013, 35:121-6. 10.4103\/0253-7176.116232","journal-title":"Indian J Psychol Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025. Diabetes Care. 2025, 48:S27-49. 10.2337\/dc25-S002","journal-title":"Diabetes Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","author":"Sibbing D","year":"2010","unstructured":"Sibbing D, Koch W, Gebhard D, et al.. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010, 121:512-8. 10.1161\/CIRCULATIONAHA.109.885194","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet JP","year":"2009","unstructured":"Collet JP, Hulot JS, Pena A, et al.. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009, 373:309-17. 10.1016\/S0140-6736(08)61845-0","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2017.07.022","article-title":"Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"11","author":"Cavallari LH","year":"2018","unstructured":"Cavallari LH, Lee CR, Beitelshees AL, et al.. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2018, 11:181-91. 10.1016\/j.jcin.2017.07.022","journal-title":"JACC Cardiovasc Interv"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-051921-092701","article-title":"Pharmacogenetics of antiplatelet therapy","volume":"63","author":"Castrichini M","year":"2023","unstructured":"Castrichini M, Luzum JA, Pereira N. Pharmacogenetics of antiplatelet therapy. Annu Rev Pharmacol Toxicol. 2023, 63:211-29. 10.1146\/annurev-pharmtox-051921-092701","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.06.014","article-title":"Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial","volume":"168","author":"Xie X","year":"2013","unstructured":"Xie X, Ma YT, Yang YN, et al.. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. Int J Cardiol. 2013, 168:3736-40. 10.1016\/j.ijcard.2013.06.014","journal-title":"Int J Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2023.01.363","article-title":"Clinical impact of CYP2C19 genotype on clopidogrel-based antiplatelet therapy after percutaneous coronary intervention","volume":"16","author":"Lee SH","year":"2023","unstructured":"Lee SH, Jeong YH, Hong D, et al.. Clinical impact of CYP2C19 genotype on clopidogrel-based antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv. 2023, 16:829-43. 10.1016\/j.jcin.2023.01.363","journal-title":"JACC Cardiovasc Interv"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3741","article-title":"CYP2C19 polymorphisms and clinical outcomes following percutaneous coronary intervention in the million Veteran program","volume":"118","author":"Chanfreau-Coffinier C","year":"2025","unstructured":"Chanfreau-Coffinier C, Friede KA, Plomondon ME, et al.. CYP2C19 polymorphisms and clinical outcomes following percutaneous coronary intervention in the million Veteran program. Clin Pharmacol Ther. 2025, 118:876-84. 10.1002\/cpt.3741","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/508046-association-between-diabetes-mellitus-and-cytochrome-p450-family-2-subfamily-c-member-19-cyp2c19-loss-of-function-allele-carriage-among-patients-undergoing-coronary-artery-bypass-grafting-a-cross-sectional-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:31:58Z","timestamp":1783085518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/508046-association-between-diabetes-mellitus-and-cytochrome-p450-family-2-subfamily-c-member-19-cyp2c19-loss-of-function-allele-carriage-among-patients-undergoing-coronary-artery-bypass-grafting-a-cross-sectional-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.111991","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,3]]}}}